Interleukin-6 and tumor necrosis factor-α in patients with obstructive sleep apnea-hypopnea syndrome

被引:66
作者
Imagawa, S [1 ]
Yamaguchi, Y
Ogawa, K
Obara, N
Suzuki, N
Yamamoto, M
Nagasawa, T
机构
[1] Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba 3058575, Japan
[2] Ctr Sleep Resp Disorder, Fukuoka, Japan
[3] Univ Tsukuba, Inst Basic Med Sci, Tsukuba 3058575, Japan
[4] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba 3058575, Japan
关键词
body mass index; interleukin-6; sleep apnea; tumor necrosis factor-alpha; vascular endothelial growth factor;
D O I
10.1159/000075645
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: In previous studies, significantly elevated levels of vascular endothelial growth factor (VEGF) have been reported in patients with severe obstructive sleep apnea-hypopnea syndrome (OSAHS). On the other hand, plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) have been significantly higher in mild sleep apneics than in normal controls. However, this study included a small number of patients and milder cases of OSAHS. Objectives and Methods: To assess the involvement of IL-6 and TNF-alpha in VEGF increases in patients with severe OSAHS, serum levels of IL-6 and TNF-alpha were determined in patients with severe OSAHS (n = 110) and compared to those of controls (n = 45) using an enzyme-linked immunosorbent assay. Results: No significant increase in IL-6 or TNF-alpha was detected in the present study cohort. However, the body mass index was significantly correlated with the severity of the apnea-hypopnea index. Conclusions: These data suggest that the elevation in VEGF is not directly related to IL-6 or TNF-alpha levels. However, the question of whether VEGF is the cause or the result of OSAHS remains to be determined. Further studies are needed to clarify the role of IL-6 and TNF-alpha in the pathogenesis of OSAHS, in which obesity should be entered as an independent factor. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:24 / 29
页数:6
相关论文
共 30 条
[1]   HERMAN-AWARD-LECTURE, 1995 - INFECTION-INDUCED MALNUTRITION - FROM CHOLERA TO CYTOKINES [J].
BEISEL, WR .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1995, 62 (04) :813-819
[2]   Interleukin-6 in the injured patient marker of injury or mediator of inflammation? [J].
Biffl, WL ;
Moore, EE ;
Moore, FA ;
Peterson, VM .
ANNALS OF SURGERY, 1996, 224 (05) :647-664
[3]   Major surgery increases serum levels of vascular endothelial growth factor only temporarily [J].
Bondestam, J ;
Salven, P ;
Jääskelä-Saari, H ;
Ikonen, T ;
Lepäntalo, M ;
Mattila, S ;
Joensuu, H .
AMERICAN JOURNAL OF SURGERY, 2000, 179 (01) :57-59
[4]  
CHRISTOU H, 1993, AM J RESP CELL MOL B, V18, P768
[5]  
deCourten M, 1997, DIABETIC MED, V14, P200, DOI 10.1002/(SICI)1096-9136(199703)14:3<200::AID-DIA336>3.0.CO
[6]  
2-V
[7]  
FOX GL, 1981, BRIT J ANAESTH, V83, P811
[8]   Circulating vascular endothelial growth factor in patients with colorectal cancer [J].
Fujisaki, K ;
Mitsuyama, K ;
Toyonaga, A ;
Matsuo, K ;
Tanikawa, K .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (02) :249-252
[9]   Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea [J].
Gozal, D ;
Lipton, AJ ;
Jones, KL .
SLEEP, 2002, 25 (01) :59-65
[10]   Vascular endothelial growth factor in exercising humans under different environmental conditions [J].
Gunga, HC ;
Kirsch, K ;
Röcker, L ;
Behn, C ;
Koralewski, E ;
Davila, EH ;
Estrada, MI ;
Johannes, B ;
Wittels, P ;
Jelkmann, W .
EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY AND OCCUPATIONAL PHYSIOLOGY, 1999, 79 (06) :484-490